BRAF V600E Mutation Positive, Metastatic Colorectal Cancer
Conditions
Keywords
first line, retrospective study, mCRC, BRAF V600E
Brief summary
The presence of a BRAFV600E mutation is considered a marker of poor prognosis in patients with mCRC, and findings from clinical trials have largely remained inconclusive regarding the efficacy of first line treatments for BRAF-mutant mCRC patients. In the absence of targeted/specific treatment for BRAF-mutant mCRC, treatment practices can vary based on local practices and guidelines. There is, therefore, an unmet need to document the current practices for first-line treatment of BRAF-mutant mCRC, and their effectiveness and safety in a real-world setting. This real-world, multicenter non-interventional study (NIS) will describe the treatment patterns, effectiveness and safety of current treatment regimens in BRAFV600E mutant mCRC patients in Europe, with the aim to put the clinical study findings of the ongoing Phase 2, single-arm, open label trial (ANCHOR) into context of the current treatment landscape excluding investigational therapies. Additionally, the NIS output may be used to support future health technology assessment submissions and publications.
Detailed description
This retrospective, multi-center longitudinal study on BRAFV600E mutant mCRC patients will be conducted in Europe to characterize the first-line treatment patterns. All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between January 1st, 2016 and December 31st, 2018 (both days inclusive) with drugs registered for mCRC in respective country will be eligible to participate. The study will not provide or recommend any treatment or procedure; all decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices and all eligible patients will be considered for enrollment. The target countries for patient enrollment will include Germany, France, Italy, United Kingdom, Spain, Belgium, Austria and the Netherlands. Approximately 300 adult patients (≥18 years) from a mix of academic and non-academic sites (up to 65 sites) will be enrolled.
Interventions
OTHERNon interventional
All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Sponsors
Clinact
Pierre Fabre Medicament
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of histologically or cytologically confirmed CRC that is metastatic and unresectable * Presence of BRAFV600E mutation in tumor tissue, as confirmed by a local assay * Initiated first-line treatment with drugs registered for mCRC in the respective country at the time of treatment between January 1st, 2016 and December 31st, 2018 (both days inclusive) * Provision of informed consent or non-opposition to the patient (or next of kin, if applicable) for the use of data, according to local regulations
Exclusion criteria
Patients will be excluded from the study if they fulfil any of the following criteria: * Patients with another concomitant cancer at the time of diagnosis\* * Patients participating in interventional trials on investigational drugs at the time of initiation of first-line treatment * Except for non-metastatic non-melanoma skin cancers, or in situ or benign neoplasms; a cancer will be considered concomitant if it occurs within 5 years of mCRC diagnosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | time from treatment initiation (for mCRC) up to 31 December 2020 | Switch in mCRC first-line SACT treatment in BRAFV600E mutant mCRC patients. |
| Duration of Treatment for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | time from treatment initiation (for mCRC) up to 31 December 2020 | First-line SACT treatment patterns in BRAFV600E mutant mCRC patients described by Duration of Treatment |
| Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | time from treatment initiation (for mCRC) up to 31 December 2020 | First-line SACT treatment patterns in BRAFV600E mutant mCRC patients described by agent or combination of agents received |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020 | complete response (CR) or partial response (PR), during the first line treatment Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR |
| Time to Treatment Cessation | from the date of the start of first-line treatment for mCRC until the documented disease progression up to 31 December 2020 | the length of time between initiation of first-line treatment for mCRC and documented disease progression (or start of subsequent Line Of Treatment (LOT), if disease progression is not well documented in patient medical record), treatment discontinuation or switch to another treatment (defined as change from one treatment regimen to another treatment regimen, e.g., change from FOLFOX-based regimen to FOLFIRI or irinotecan-based regimen) |
| Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020 | Description of testing procedures of BRAF mutation testing since mCRC diagnosis and since first-line treatment for mCRC |
| Demographic and Clinical Characteristics | from the date of the start of first-line treatment for mCRC up to 31 December 2020 | Description of the demographic and clinical profile of patients at the time of treatment initiation (for mCRC) TNM stage of colorectal cancer. Stage I: Cancer is still in the inner lining, but has grown through the mucosa of the colon and invaded the muscle layer. Stage II: The cancer has grown beyond the mucosa of the colon but has not spread to the lymph nodes Stage III: The cancer has spread to the lymph nodes near the colon, it has not spread further. Stage IV: The cancer has spread outside of the colon and has been carried through the lymph and blood systems to distant parts of the body, this is known as metastasis. |
| Description of BRAF Mutation Testing Timing in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020 | Time to BRAF mutation testing since mCRC diagnosis and since first-line treatment for mCRC |
| Progression-free Survival (PFS) | from the date of the start of first-line treatment for mCRC up to 31 December 2020 | the length of time between initiation of first-line treatment for mCRC and the first documented disease progression or death. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
| Overall Survival (OS) | from the date of the start of first-line treatment for mCRC up to 31 December 2020 | length of time between first-line treatment initiation (for mCRC) and death (due to any cause) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020 | Description of the types of treatments after first-line SACT treatment (2nd-line to 7th-line) in BRAFV600E Mutant mCRC Patients. |
| Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020 | Description of reasons for alteration or discontinuation of first-line treatment for mCRC in BRAFV600E Mutant mCRC Patients |
Countries
Austria, Belgium, France, Germany, Italy, Spain, United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Non Interventional All BRAFV600E mutant patients having initiated a first-line treatment for mCRC between 01 January, 2016 and 31 December, 2018 (both days inclusive) with drugs registered for mCRC in respective country
Non Interventional study: Non Interventional study | 255 |
| Total | 255 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | ineligible due to inclusion/exclusion criteria | 15 |
| Overall Study | treatment outside standard of care | 4 |
Baseline characteristics
| Characteristic | Non Interventional | — |
|---|---|---|
| 1st line therapy received for the mCRC Doublet chemotherapy (CT) | 72 Participants | — |
| 1st line therapy received for the mCRC Doublet CT + TT | 118 Participants | — |
| 1st line therapy received for the mCRC monotherapy +/- Targeted Therapy (TT) | 17 Participants | — |
| 1st line therapy received for the mCRC Triplet CT | 8 Participants | — |
| 1st line therapy received for the mCRC Triplet CT + TT | 40 Participants | — |
| Age, Customized ≤ 60 years | 87 Participants | — |
| Age, Customized 61-70 years | 68 Participants | — |
| Age, Customized > 70 years | 100 Participants | — |
| Anthropometry - Body Mass Index (BMI) | 25.42 kg/m² STANDARD_DEVIATION 5.44 | — |
| Carbohydrate antigen 19-9 (CA 19.9) levels | 149.18 U/mL STANDARD_DEVIATION 220.75 | — |
| Carcinoembryonic antigen (CEA) levels | 16.20 ng/mL STANDARD_DEVIATION 18.46 | — |
| Characterization of metastasis | 4.75 months STANDARD_DEVIATION 12.25 | — |
| C-reactive protein levels | 13.99 mg/L STANDARD_DEVIATION 12.45 | — |
| Disease stage at initial diagnosis I | 4 Participants | — |
| Disease stage at initial diagnosis II | 24 Participants | — |
| Disease stage at initial diagnosis III | 48 Participants | — |
| Disease stage at initial diagnosis IV | 150 Participants | — |
| Hemoglobin levels | 11.93 g/dL STANDARD_DEVIATION 1.91 | — |
| Hemoglobin levels - normal/abnormal Abnormal | 79 Participants | — |
| Hemoglobin levels - normal/abnormal Normal (between [12 ;16] g/dL) | 88 Participants | — |
| Histology at initial diagnosis Adenocarcinoma | 252 Participants | — |
| Histology at initial diagnosis Other carcinoma | 1 Participants | — |
| Leucocyte levels | 9.07 10^9 cells/L STANDARD_DEVIATION 3.33 | — |
| Location of metastasis Abdomen (including 7 patients with ovaries) | 12 Participants | — |
| Location of metastasis Bone | 8 Participants | — |
| Location of metastasis Central Nervous System | 2 Participants | — |
| Location of metastasis Liver | 148 Participants | — |
| Location of metastasis Liver only | 48 Participants | — |
| Location of metastasis Lungs | 68 Participants | — |
| Location of metastasis Lymph nodes | 89 Participants | — |
| Location of metastasis Other | 25 Participants | — |
| Location of metastasis Peritoneum | 112 Participants | — |
| Method of RAS testing Next generation sequencing (NGS) | 89 Participants | — |
| Method of RAS testing Other | 60 Participants | — |
| Method of RAS testing Polymerase chain reaction (PCR) | 81 Participants | — |
| Microsatellite instability (MSI) testing MSI high | 36 Participants | — |
| Microsatellite instability (MSI) testing MSI low | 10 Participants | — |
| Microsatellite instability (MSI) testing MSI stable | 103 Participants | — |
| Microsatellite instability (MSI) testing MSI unknown | 4 Participants | — |
| MMR gene (if MSI was measured) dMMR | 29 Participants | — |
| MMR gene (if MSI was measured) pMMR | 90 Participants | — |
| Neutrophil (absolute count) | 6.19 10^9 cells/L STANDARD_DEVIATION 2.96 | — |
| Neutrophil (differential count) | 67.75 percentage of total blood cells STANDARD_DEVIATION 11.77 | — |
| Number of comorbidities | 0.8 comorbidities STANDARD_DEVIATION 1 | — |
| Number of metastatic sites 1 site | 115 Participants | — |
| Number of metastatic sites 2 sites | 82 Participants | — |
| Number of metastatic sites ≥3 sites | 58 Participants | — |
| Number of patients receiving radiotherapy for CRC or mCRC | 29 Participants | — |
| Number of patients with at least one SACT (Systemic anti-cancer therapy) treatment | 40 Participants | — |
| Number of patients with at least one surgery for either CRC or mCRC | 163 Participants | — |
| Patients with at least one comorbidity | 129 Participants | — |
| Performance Status ECOG 0 | 80 Participants | — |
| Performance Status ECOG 1 | 56 Participants | — |
| Performance Status ECOG 2 | 10 Participants | — |
| Performance Status ECOG 3 | 4 Participants | — |
| Platelet levels | 342.64 10^9 platelets/L STANDARD_DEVIATION 142.86 | — |
| Primary tumor location left and/or rectum | 83 Participants | — |
| Primary tumor location other (left and right or transverse or right and rectum or not applicable) | 38 Participants | — |
| Primary tumor location right only | 134 Participants | — |
| Race and Ethnicity Not Collected | — | — Participants |
| RAS testing Mutated | 16 Participants | — |
| RAS testing Unknown | 1 Participants | — |
| RAS testing Wild type | 217 Participants | — |
| Region of Enrollment Austria | 4 Participants | — |
| Region of Enrollment Belgium | 28 Participants | — |
| Region of Enrollment France | 74 Participants | — |
| Region of Enrollment Germany | 45 Participants | — |
| Region of Enrollment Italy | 52 Participants | — |
| Region of Enrollment Spain | 35 Participants | — |
| Region of Enrollment United Kingdom | 17 Participants | — |
| Serum albumin levels | 10.17 g/dL STANDARD_DEVIATION 14.43 | — |
| Sex: Female, Male Female | 149 Participants | — |
| Sex: Female, Male Male | 106 Participants | — |
| Types of comorbidity Acquired immunodeficiency syndrome (AIDS) | 1 Participants | — |
| Types of comorbidity Cerebrovascular disease | 1 Participants | — |
| Types of comorbidity Chronic pulmonary disease | 12 Participants | — |
| Types of comorbidity Congestive heart failure | 4 Participants | — |
| Types of comorbidity Diabetes mellitus with end-organ damage | 9 Participants | — |
| Types of comorbidity Heart rhythm disorder | 19 Participants | — |
| Types of comorbidity Ischemic cardiac disorder | 12 Participants | — |
| Types of comorbidity Moderate or severe liver disease | 6 Participants | — |
| Types of comorbidity Moderate or severe renal disease | 4 Participants | — |
| Types of comorbidity Peripheral vascular disease | 15 Participants | — |
| Types of comorbidity Rheumatic or connective tissue disease | 12 Participants | — |
| Types of comorbidity Treated hypertension | 100 Participants | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 206 / 255 |
| other Total, other adverse events | 104 / 255 |
| serious Total, serious adverse events | 40 / 255 |
Outcome results
Primary
Duration of Treatment for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
First-line SACT treatment patterns in BRAFV600E mutant mCRC patients described by Duration of Treatment
Time frame: time from treatment initiation (for mCRC) up to 31 December 2020
Population: A total of 255 patients were included in the full analysis set (FAS). Data for 2 patients were not available.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Non Interventional | Duration of Treatment for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | 6.04 months | Standard Deviation 5.79 |
Primary
Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients
Switch in mCRC first-line SACT treatment in BRAFV600E mutant mCRC patients.
Time frame: time from treatment initiation (for mCRC) up to 31 December 2020
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch to other treatment | 80 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch to other treatment: maintenance | 30 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch to: Tomiri | 1 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch to: Fluoropyrimidine + (Leucovorin or Folinic Acid) | 2 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch to: Other | 4 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: BRAFi + Other | 1 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: Fluoropyrimidine monotherapy | 6 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: Fluoropyrimidine monotherapy / Bevacizumab | 19 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: Fluoropyrimidine monotherapy / Panitumumab | 2 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: Fluoropyrimidine + (Leucovorin or Folinic Acid) | 1 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab | 1 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: Other | 4 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Reason for switch: toxicity | 24 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Reason for switch: lack of response | 13 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Reason for switch: other | 13 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch to: FOLFOX | 21 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch to: CAPOX | 1 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch to: FOLFIRI | 16 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch to: Fluoropyrimidine monotherapy | 27 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch to: FOLFOXIRI | 4 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch to: FOLFIRINOX | 3 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch to: BRAFi + Other | 1 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | If switch with FOLFOX, CAPOX, FOLFIRI, Fluoropyrimidine or FOLFIXIRI - | 53 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | - then, in combination with: Panitumumab | 4 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | - then, in combination with: Cetuximab | 1 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | - then, in combination with: Bevacizumab | 48 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: CAPOX / Bevacizumab | 1 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: FOLFIRI | 6 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: FOLFIRI / Bevacizumab | 8 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: FOLFIRI / Cetuximab | 1 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: FOLFIRI / Panitumumab | 1 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: FOLFIRINOX | 2 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: FOLFIRINOX / Bevacizumab | 1 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: FOLFOX | 6 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: FOLFOX / Bevacizumab | 14 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: FOLFOX / Panitumumab | 1 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: FOLFOXIRI / Bevacizumab | 4 Participants |
| Non Interventional | Switch in mCRC First-line Systemic Anticancer Therapy (SACT) Treatment in BRAFV600E Mutant mCRC Patients | Switch regiment: Tomiri | 1 Participants |
Primary
Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients
First-line SACT treatment patterns in BRAFV600E mutant mCRC patients described by agent or combination of agents received
Time frame: time from treatment initiation (for mCRC) up to 31 December 2020
Population: \*treated as doublet CT + anti-EGFR for analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet chemotherapy (CT) | 72 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Monotherapy +/- targetted therapy (TT) | 17 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Monotherapy +/- TT : : Fluropyrimidine monotherapy | 6 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Monotherapy +/- TT : : Fluropyrimidine monotherapy / Bevacizumab | 10 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Monotherapy +/- TT : : Fluropyrimidine monotherapy / Panitumumab | 1 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT : : CAPOX | 11 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT : : FOLFIRI | 7 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT : : FOLFOX | 49 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT : : Fluoropyrimidine + (Irinotecan or Folic Acid) | 3 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT : : XELIRI | 2 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT + TT | 118 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT + TT : Doublet CT + anti-VEGF | 99 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT + TT : Doublet CT + anti-VEGF : CAPOX / Bevacizumab | 8 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT + TT : Doublet CT + anti-VEGF : FOLFIRI / Aflibercept | 2 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT + TT : Doublet CT + anti-VEGF : FOLFIRI / Bevacizumab | 20 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT + TT : Doublet CT + anti-VEGF : FOLFOX / Bevacizumab | 69 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT + TT : Doublet CT + anti-EGFR | 19 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT + TT : Doublet CT + anti-EGFR : FOLFIRI / Cetuximab | 3 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT + TT : Doublet CT + anti-EGFR : FOLFIRI / Panitumumab | 2 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT + TT : Doublet CT + anti-EGFR : Tomiri / Panitumumab | 1 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT + TT : Doublet CT + anti-EGFR : FOLFOX / Cetuximab | 5 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT + TT : Doublet CT + anti-EGFR : FOLFOX / Panitumumab | 7 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Doublet CT + TT : Doublet CT + anti-EGFR : FOLFOX / Cetuximab + Avelumab* | 1 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Triplet CT | 8 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Triplet CT : : FOLFIRINOX | 2 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Triplet CT : : FOLFOXIRI | 6 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Triplet CT + TT | 40 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Triplet CT + TT : Triplet + anti-VEGF | 38 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Triplet CT + TT : Triplet + anti-VEGF : FOLFIRINOX / Bevacizumab | 4 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Triplet CT + TT : Triplet + anti-VEGF : FOLFOXIRI / Bevacizumab | 34 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Triplet CT + TT : Triplet + anti-EGFR | 2 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Triplet CT + TT : Triplet + anti-EGFR : FOLFOXIRI / Cetuximab | 1 Participants |
| Non Interventional | Treatment Patterns for First-line Systemic Anticancer Therapy (SACT) in BRAFV600E Mutant mCRC Patients | Triplet CT + TT : Triplet + anti-EGFR : FOLFOXIRI / Panitumumab | 1 Participants |
Secondary
Demographic and Clinical Characteristics
Description of the demographic and clinical profile of patients at the time of treatment initiation (for mCRC) TNM stage of colorectal cancer. Stage I: Cancer is still in the inner lining, but has grown through the mucosa of the colon and invaded the muscle layer. Stage II: The cancer has grown beyond the mucosa of the colon but has not spread to the lymph nodes Stage III: The cancer has spread to the lymph nodes near the colon, it has not spread further. Stage IV: The cancer has spread outside of the colon and has been carried through the lymph and blood systems to distant parts of the body, this is known as metastasis.
Time frame: from the date of the start of first-line treatment for mCRC up to 31 December 2020
Population: Disease stage at initial diagnosis of CRC by first line treatment regimen Data were available for 226 of the 255 patients included in the FAS
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Non Interventional | Demographic and Clinical Characteristics | Doublet CT | TNM Stage IV | 41 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Triplet CT | TNM Stage I | 0 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Doublet CT + TT | TNM Stage I | 2 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Monotherapy +/- TT | TNM Stage I | 0 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Monotherapy +/- TT | TNM Stage II | 3 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Monotherapy +/- TT | TNM Stage III | 4 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Monotherapy +/- TT | TNM Stage IV | 8 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Doublet CT | TNM Stage I | 1 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Doublet CT | TNM Stage II | 7 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Doublet CT | TNM Stage III | 10 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Doublet CT + TT | TNM Stage II | 10 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Doublet CT + TT | TNM Stage III | 26 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Doublet CT + TT | TNM Stage IV | 75 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Triplet CT | TNM Stage III | 2 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Triplet CT | TNM Stage IV | 4 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Triplet CT + TT | TNM Stage I | 1 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Triplet CT + TT | TNM Stage II | 4 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Triplet CT + TT | TNM Stage III | 6 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Triplet CT + TT | TNM Stage IV | 22 Participants |
| Non Interventional | Demographic and Clinical Characteristics | Triplet CT | TNM Stage II | 0 Participants |
Secondary
Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Description of testing procedures of BRAF mutation testing since mCRC diagnosis and since first-line treatment for mCRC
Time frame: from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020
Population: Data not available for all patients.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Number of BRAF testing: 1 | 244 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Number of BRAF testing: 2 | 11 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Timing of 1st BRAF testing: before 1L (2 to 38 months before 1st line initiation) | 62 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Timing of 1st BRAF testing: before 1L (less than 2 months before 1st line initiation) | 140 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Timing of 1st BRAF testing: during 1L | 21 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Timing of 1st BRAF testing: after 1L and before 2L | 1 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Timing of 1st BRAF testing: during 2L | 1 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | BRAF test sample: tumor sample | 252 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | BRAF test sample: ctDNA | 3 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | If tumor sample, tumor sample tested: archival | 175 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | If tumor sample, tumor sample tested: fresh | 53 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Method used: PCR | 104 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Method used: NGS | 86 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Method used: Other | 10 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Method used: high resolution melting | 4 Participants |
| Non Interventional | Description of BRAF Mutation Testing Procedure in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Method used: mass spectrometry | 22 Participants |
Secondary
Description of BRAF Mutation Testing Timing in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients
Time to BRAF mutation testing since mCRC diagnosis and since first-line treatment for mCRC
Time frame: from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020
Population: Data not available for all patients.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Non Interventional | Description of BRAF Mutation Testing Timing in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Time from metastatic diagnosis to 1st BRAF mutation testing (if after metastatic diagnosis) | 0.6 months | Standard Error 1.7 |
| Non Interventional | Description of BRAF Mutation Testing Timing in Regards With the First-line Treatment in BRAFV600E Mutant mCRC Patients | Time from metastatic diagnosis to 1st BRAF mutation testing (if before metastatic diagnosis) | 6.1 months | Standard Error 7.9 |
Secondary
Overall Response Rate (ORR)
complete response (CR) or partial response (PR), during the first line treatment Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time frame: from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020
Population: Data were available for 221 of the 255 patients included in the FAS
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Non Interventional | Overall Response Rate (ORR) | 37.1 percentage of participants |
Secondary
Overall Survival (OS)
length of time between first-line treatment initiation (for mCRC) and death (due to any cause)
Time frame: from the date of the start of first-line treatment for mCRC up to 31 December 2020
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Non Interventional | Overall Survival (OS) | 12.68 months |
Secondary
Progression-free Survival (PFS)
the length of time between initiation of first-line treatment for mCRC and the first documented disease progression or death. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: from the date of the start of first-line treatment for mCRC up to 31 December 2020
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Non Interventional | Progression-free Survival (PFS) | 5.98 months |
Secondary
Time to Treatment Cessation
the length of time between initiation of first-line treatment for mCRC and documented disease progression (or start of subsequent Line Of Treatment (LOT), if disease progression is not well documented in patient medical record), treatment discontinuation or switch to another treatment (defined as change from one treatment regimen to another treatment regimen, e.g., change from FOLFOX-based regimen to FOLFIRI or irinotecan-based regimen)
Time frame: from the date of the start of first-line treatment for mCRC until the documented disease progression up to 31 December 2020
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Non Interventional | Time to Treatment Cessation | 4.83 months |
Other Pre-specified
Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients
Description of the types of treatments after first-line SACT treatment (2nd-line to 7th-line) in BRAFV600E Mutant mCRC Patients.
Time frame: from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020
Population: Not all patients went through all lines of treatment.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | CAPOX / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | Irinotecan / Cetuximab | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | Fluoropyrimidine monotherapy / Panitumumab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | FOLFIRI | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | Other | 8 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | Panitumumab monotherapy | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | CAPOX / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | Fluoropyrimidine monotherapy / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | CAPOX | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | FOLFIRI / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | BRAFi | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | CAPOX / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | XELIRI / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | BRAFi | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | BRAFi / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | BRAFi / Cetuximab + Irinotecan | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | BRAFi+ Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | BRAFi / MEKi / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | BRAFi / MEKi / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | Cetuximab monotherapy | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | FOLFIRI | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | FOLFIRI / Aflibercept | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | FOLFIRI / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | BRAFi / Cetuximab | 7 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | BRAFi / Cetuximab + Irinotecan | 4 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | BRAFi+ Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | BRAFi / MEKi / Cetuximab | 16 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | BRAFi / MEKi / Panitumumab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | CAPOX | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | Cetuximab monotherapy | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | FOLFIRI | 19 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | FOLFIRI / Aflibercept | 7 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | FOLFIRI / Bevacizumab | 20 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | FOLFIRI / Cetuximab | 8 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | FOLFIRI / Panitumumab | 5 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | FOLFOX | 4 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | FOLFIRI / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | FOLFOX | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | FOLFOX / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | FOLFOX / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | FOLFOX / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | FOLFOXIRI | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | FOLFOX / Bevacizumab | 7 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | FOLFOX / Cetuximab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | FOLFOX / Panitumumab | 3 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | FOLFOXIRI | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | FOLFOXIRI / Bevacizumab | 6 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | Fluoropyrimidine monotherapy | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | Fluoropyrimidine monotherapy / Bevacizumab | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | Fluoropyrimidine + (Leucovorin or Folinic Acid) | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | Irinotecan | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | Irinotecan / Cetuximab | 4 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | Irinotecan / Panitumumab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | Other | 7 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | Panitumumab monotherapy | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | XELIRI / Bevacizumab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | BRAFi | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | Fluoropyrimidine monotherapy / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 2nd | Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | BRAFi / Cetuximab | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | BRAFi / Cetuximab + Irinotecan | 5 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | BRAFi+ Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | BRAFi / MEKi / Cetuximab | 6 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | BRAFi / MEKi / Panitumumab | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | CAPOX | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | Cetuximab monotherapy | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | FOLFIRI | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | FOLFIRI / Aflibercept | 4 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | FOLFIRI / Bevacizumab | 9 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | FOLFIRI / Cetuximab | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | FOLFIRI / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | FOLFOX | 4 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | FOLFOX / Bevacizumab | 5 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | FOLFOX / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | FOLFOX / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | FOLFOXIRI | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | FOLFOXIRI / Bevacizumab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | Fluoropyrimidine monotherapy | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | Fluoropyrimidine monotherapy / Bevacizumab | 3 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | Fluoropyrimidine + (Leucovorin or Folinic Acid) | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | Irinotecan | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | Irinotecan / Cetuximab | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | Irinotecan / Panitumumab | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | Other | 20 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | Panitumumab monotherapy | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | XELIRI / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | BRAFi | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | CAPOX / Bevacizumab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | Fluoropyrimidine monotherapy / Panitumumab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | Other | 15 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 3rd | Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | BRAFi / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | BRAFi / Cetuximab + Irinotecan | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | BRAFi+ Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | BRAFi / MEKi / Cetuximab | 3 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | BRAFi / MEKi / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | CAPOX | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | Cetuximab monotherapy | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | FOLFIRI | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | FOLFIRI / Aflibercept | 4 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | FOLFIRI / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | FOLFIRI / Cetuximab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | FOLFIRI / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | FOLFOX | 4 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | FOLFOX / Bevacizumab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | FOLFOX / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | FOLFOX / Panitumumab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | FOLFOXIRI | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | FOLFOXIRI / Bevacizumab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | Fluoropyrimidine monotherapy | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | Fluoropyrimidine monotherapy / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | Fluoropyrimidine + (Leucovorin or Folinic Acid) | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | Irinotecan | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | Irinotecan / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | Panitumumab monotherapy | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | XELIRI / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | BRAFi | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | CAPOX / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 4th line | Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | BRAFi / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | BRAFi / Cetuximab + Irinotecan | 2 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | BRAFi+ Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | BRAFi / MEKi / Cetuximab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | BRAFi / MEKi / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | CAPOX | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | Cetuximab monotherapy | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | FOLFIRI / Aflibercept | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | FOLFIRI / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | FOLFIRI / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | FOLFIRI / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | FOLFOX | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | FOLFOX / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | FOLFOX / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | FOLFOX / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | FOLFOXIRI | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | FOLFOXIRI / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | Fluoropyrimidine monotherapy | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | Fluoropyrimidine monotherapy / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | Fluoropyrimidine + (Leucovorin or Folinic Acid) | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | Irinotecan | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | Irinotecan / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 5th line | Irinotecan / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | FOLFOXIRI / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | Fluoropyrimidine monotherapy | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | Fluoropyrimidine monotherapy / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | Fluoropyrimidine + (Leucovorin or Folinic Acid) | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | Irinotecan | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | Irinotecan / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | Irinotecan / Panitumumab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | Other | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | Panitumumab monotherapy | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | XELIRI / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | Fluoropyrimidine monotherapy / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 6th line | Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | BRAFi / Cetuximab | 1 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | BRAFi / Cetuximab + Irinotecan | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | BRAFi+ Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | BRAFi / MEKi / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | BRAFi / MEKi / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | CAPOX | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | Cetuximab monotherapy | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | FOLFIRI | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | FOLFIRI / Aflibercept | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | FOLFIRI / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | FOLFIRI / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | FOLFIRI / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | FOLFOX | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | FOLFOX / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | FOLFOX / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | FOLFOX / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | FOLFOXIRI | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | FOLFOXIRI / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | Fluoropyrimidine monotherapy | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | Fluoropyrimidine monotherapy / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | Fluoropyrimidine + (Leucovorin or Folinic Acid) | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | Fluoropyrimidine + (Leucovorin or Folinic Acid) / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | Irinotecan | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | Irinotecan / Cetuximab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | Irinotecan / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | Other | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | Panitumumab monotherapy | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | XELIRI / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | BRAFi | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | CAPOX / Bevacizumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | Fluoropyrimidine monotherapy / Panitumumab | 0 Participants |
| Non Interventional | Other Types of SACT Treatment Line Regiments After First-line Treatment for mCRC in BRAFV600E Mutant mCRC Patients | 7th line | Fluoropyrimidine + (Leucovorin or Folinic Acid) / Bevacizumab | 0 Participants |
Other Pre-specified
Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients
Description of reasons for alteration or discontinuation of first-line treatment for mCRC in BRAFV600E Mutant mCRC Patients
Time frame: from the date of the start of first-line treatment for mCRC until the end of first-line treatment up to 31 December 2020
Population: \*due to other reasons than progression or toxicity.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Patient with treatment alteration | 137 Participants |
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Most important reason for treatment alteration: Planned alteration | 10 Participants |
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Most important reason for treatment alteration: Toxicity | 100 Participants |
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Most important reason for treatment alteration: Poor performance status of patient | 6 Participants |
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Most important reason for treatment alteration: Other | 16 Participants |
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Patient with treatment discontinuation | 248 Participants |
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Most important reason for treatment discontinuation: Progression | 158 Participants |
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Most important reason for treatment discontinuation: Toxicity | 19 Participants |
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Most important reason for treatment discontinuation: BRAF test available | 5 Participants |
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Most important reason for treatment discontinuation: Planned discontinuation | 21 Participants |
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Most important reason for treatment discontinuation: Patient choice | 6 Participants |
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Most important reason for treatment discontinuation: Poor performance status of patient | 16 Participants |
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Most important reason for treatment discontinuation: Death* | 4 Participants |
| Non Interventional | Reasons for Alteration or Discontinuation of First-line Treatment in BRAFV600E Mutant mCRC Patients | Most important reason for treatment discontinuation: Other | 9 Participants |